Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Organisation › Details

Xigen S.A.

Xigen, a Swiss biopharmaceutical company founded as a spin-off of the Centre Hospitalier Universitaire Vaudois (CHUV), specializes in the research and development of innovative therapeutic peptides with a focus on inflammatory diseases. The Company’s technology has enabled the design and synthesis of cell-penetrating peptides with enhanced metabolic stability, using proprietary carrier motifs to selectively deliver them to intracellular targets in disease relevant cell types. Xigen’s lead compound Brimapitide (XG-102) is advancing through pre-clinical development with programs in ocular inflammation, urology, nephrology and Alzheimer’s disease. *

 

Period Start 2002-01-14 splitoff
  Predecessor CHUV Centre Hospitalier Universitaire Vaudois (University Hospital Lausanne)
Products Industry anti-inflammatory drug
  Industry 2 brimapitide (XG-102)
Person Person Bonny, Christophe (Enterome 201609– CSO before Bicycle Therapeutics + Xigen + Univ Hospital Lausanne)
     
Region Region Epalinges VD
  Country Switzerland
  Street 4 Route de la Corniche
  City 1066 Epalinges VD
  Tel +41-21-321-1080
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Xigen S.A.. (1/5/17). "Press Release: Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease". Geneva.
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Xigen S.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top